The Artificial Coma/Medically Induced Coma Market Size was valued at USD 0.8 Billion in 2022 and is projected to grow from USD 0.82 Billion in 2023 to USD 1.09 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.50% during the forecast period (2023 - 2032). Alarming increase in traumatic brain injury prevalence and increase in government and private funding for the expansion of the healthcare industries are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for artificial coma/medically induced coma supplements is being driven by the rising infectious and chronic diseases. The prevalence of infectious and chronic diseases like cancer, diabetes, cardiovascular disease, and hypertension is rising. The aging population is also on the rise, as is the demand for anesthetic drugs, which is fueling the growth of the artificial coma market. For instance, in August 2021, scientists from Washington University School of Medicine in St. Louis and the University of Michigan completed a study for anesthetic medications that will enhance clinical results. In this investigation, anesthetic medications such as intravenous propofol are used. Research and development efforts are concentrated on anesthetic drugs that put patients into a coma during crucial surgical procedures.By 2050, one in four residents of Europe and North America maybe 65 years of age or older, according to the United Nations Department of Economic and Social Affairs.
The number of chronic disorders affecting the elderly has sharply increased due to the prevalence of older individuals, which has also increased the demand for anesthetic medications. The artificial coma/medically induced coma market is expected to develop due to increased demand to lessen discomfort during surgery, advancements in R&D activities in the biotechnology industries, pharmaceuticals and increased operations. The creation of novel pharmaceuticals for the healthcare industry is accelerating the market's expansion.
Additionally, government initiatives for drug approval and the enormous rise in anesthetic pharmaceuticals are the main drivers of the market's expansion. For instance, Desflurane Liquid for Inhalation, the first generic version of Suprane liquid from Baxter Healthcare in the United States, was introduced in January 2019 by Sandoz, a branch of Novartis. It is utilized to control artificial coma in individuals undergoing surgery. According to an article in Neurology India, the annual incidence of stroke in Asia ranged from 116 to 483/100,000. Stroke cases among younger people have grown significantly, with more severe physical effects. At the same time, traumatic brain injury is the main factor in brain tissue deterioration. In India, the incidence is three times higher than the global average (13.3 per 100,000). Because of this, the number of procedures performed rises, which is projected to fuel the expansion of the artificial coma industry. Thus, driving the artificial coma/medically induced coma market revenue.
Based on type, the Artificial Coma/Medically Induced Coma Market segmentation includes propofol and barbiturate. The propofol segment dominated the market, accounting for 58% of market revenue. The number of surgical procedures is rising yearly due to increased R&D efforts in the pharmaceutical business. This is happening for various reasons, including the aging population, the rise in chronic illnesses, and the growing acceptance of minimally invasive surgery. A popular anesthetic, propofol is used for many surgical operations, including general anesthesia, sedation, and procedural sedation. It is often used in large quantities when a new medicine is introduced.
The Artificial Coma/Medically Induced Coma Market segmentation, based on application, includes status epilepticus, stroke, traumatic brain injury, drug overdose, brain infections, and others. The stroke segment dominated the market. The rise in chronic illnesses, the aging population, lifestyle issues, and the number of people with diabetes at risk for stroke are all expected to fuel market expansion. The average number of stroke cases yearly is 15 million, of which 6 million result in death and 5 million in permanent disability. Due to the absence of awareness and memory of the stroke caution signs and symptoms, this is crucial.
Based on distribution channels, the Artificial Coma/Medically Induced Coma Market segmentation includes hospital pharmacies and drug stores & retail pharmacies. The hospital pharmacies generated the most income (70.4%). According to forecasts, the rise in the geriatric population, the prevalence of chronic diseases, the frequency of lifestyle disorders, and the number of people with diabetes who have suffered strokes would all contribute to the market's expansion. A stroke affects around 15 million people annually, 6 million perish, and 5 million suffer a lifelong disability. Due to a lack of information and memory of the stroke warning signs and symptoms, this is crucial.
Figure 1: Artificial Coma/Medically Induced Coma Market, by Distribution channel, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American artificial coma/medically induced coma market will dominate this market; Longer-term medically induced comas may now be safely induced and maintained because of developments in medical technology like ventilators and brain monitoring. This has made a larger range of individuals and illnesses eligible to use medically induced coma.
Further, the major countries studied in the market report are The US, Canada, China, Japan, German, France, the UK, Italy, Spain, India, Australia, South Korea, and Brazil.
Figure 2: ARTIFICIAL COMA/MEDICALLY INDUCED COMA MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Artificial coma/medically induced coma. The advantages of medically induced coma, such as its capacity to shield the brain from more harm and to let the body recuperate, are being recognized by healthcare experts in Europe more and more. This results in more patients using medically induced coma more frequently. Furthermore, the German Artificial coma/medically induced coma market dominated, while the UK Artificial coma/medically induced coma market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Artificial coma/medically induced coma Market will develop at the quickest CAGR. Asia Pacific is experiencing a rise in surgical operations due to various causes, including an increased prevalence of chronic illnesses, an aging population, and the growing acceptance of minimally invasive techniques. A medically induced coma is necessary for several surgical operations, such as brain surgery. Furthermore, China's Artificial coma/medically induced coma market had the highest market share. In contrast, the Asia-Pacific region's Artificial coma/medically induced coma market in India was the one that was growing the quickest.
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Artificial coma/medically induced coma market grow even more. Important market developments include contractual agreements, new product releases, acquisitions and mergers, greater investments, and collaboration with other organizations. The Artificial coma/medically induced coma industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Artificial coma/medically induced coma industry to serve clients and expand the market sector. The Artificial coma/medically induced coma industry has provided some of the most important benefits recently. PAION AG , Sandoz; and other major competitors in the Artificial coma/medically induced coma market are seeking to improve market demand by investing in R&D efforts.
A publicly traded specialty pharmaceutical company, PAION AG, offers cutting-edge medications for hospital-based sedation, anesthesia, and critical care services. Remimazolam, an intravenous, ultra-short-acting, and controlled benzodiazepine sedative/anesthetic, is the main ingredient of PAION. Remimazolam has partners in several non-European countries. Remimazolam is authorized in the United States, the EU/EEA/UK, and China, and general anesthesia in Japan and South Korea for procedural sedation. In June 2021, The UK MHRA has authorised Byfavo(R) (remimazolam besylate) in adults for procedural sedation, according to the specialised pharmaceutical firm PAION AG. An ultra-short acting intravenous benzodiazepine sedative/anesthetic is called Byfavo(R). The choice was made when the European Commission gave its consent to the EU (together with EEA nations) in March 2021.
The leader in biosimilars and generic drugs is Sandoz. Their goal is to develop cutting-edge methods that will make high-quality medication more accessible to people worldwide. Their corporate goal is to become the world's most prestigious and successful generics firm. Their worldwide portfolio, comprising over 1000 compounds and covering a wide spectrum of therapeutic areas, is expected to generate $9.2 billion in sales by 2022. Their extensive selection results in large and recurring savings for patients and payors, ensuring the viability of healthcare systems in the face of severe financial demands and freeing up cash for cutting-edge medications.In January 2019, Desflurane Liquid for Inhalation is the first Suprane liquid generic made available in the United States by Sandoz, a part of Novartis. It is utilized to control artificial coma in individuals undergoing surgery.
Key Companies in the Artificial Coma/Medically Induced Coma Market Include
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.8 Billion |
| Market Size 2023 | USD 0.82 Billion |
| Market Size 2032 | USD 1.09 Billion |
| Compound Annual Growth Rate (CAGR) | 3.50% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Piramal Group, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Fresenius Se & Co Kgaa, Astrazeneca Plc, Dr. Reddy’s Laboratory, Pfizer Inc., Viatris Inc. (Mylan N.V), B.Braun Melsungen Ag, Baxter International Inc. |
| Key Market Opportunities | · Advancement in technology |
| Key Market Dynamics | · Increase in chronic diseases |
Artificial Coma Medically Induced Coma Market Highlights:
Frequently Asked Questions (FAQ) :
The Artificial Coma/Medically Induced Coma Market size was valued at USD 0.8 Billion in 2022.
The global market is projected to grow at a CAGR of 3.50% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Piramal Group, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Fresenius Se & Co Kgaa, Astrazeneca Plc, Dr. Reddy’s Laboratory, Pfizer Inc., Viatris Inc. (Mylan N.V), B.Braun Melsungen Ag, Baxter International Inc.
The Propofol dominated the market in 2022.
The Hospital Pharmacies had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
